Clinical Trial Update: Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant [Phase 3]

View source ↗

Summary

The document reports the completed Phase 3 trial evaluating fingolimod (FTY720) for safety and efficacy in adult kidney transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Fingolimod (Gilenya) (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Kidney Transplantation | Phase 3 | Status: COMPLETED